JP2024501764A5 - - Google Patents
Info
- Publication number
- JP2024501764A5 JP2024501764A5 JP2023540910A JP2023540910A JP2024501764A5 JP 2024501764 A5 JP2024501764 A5 JP 2024501764A5 JP 2023540910 A JP2023540910 A JP 2023540910A JP 2023540910 A JP2023540910 A JP 2023540910A JP 2024501764 A5 JP2024501764 A5 JP 2024501764A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compound
- cardiomyopathy
- salt
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163134243P | 2021-01-06 | 2021-01-06 | |
| US63/134,243 | 2021-01-06 | ||
| US202163147801P | 2021-02-10 | 2021-02-10 | |
| US63/147,801 | 2021-02-10 | ||
| PCT/US2022/011336 WO2022150403A1 (en) | 2021-01-06 | 2022-01-05 | Combination therapies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501764A JP2024501764A (ja) | 2024-01-15 |
| JP2024501764A5 true JP2024501764A5 (https=) | 2025-12-26 |
Family
ID=82358297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023540910A Pending JP2024501764A (ja) | 2021-01-06 | 2022-01-05 | 併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240082242A1 (https=) |
| EP (1) | EP4274436A4 (https=) |
| JP (1) | JP2024501764A (https=) |
| KR (1) | KR20230129250A (https=) |
| AU (1) | AU2022205937A1 (https=) |
| CA (1) | CA3206848A1 (https=) |
| IL (1) | IL304054A (https=) |
| WO (1) | WO2022150403A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| EP4146215A4 (en) * | 2020-05-04 | 2024-05-01 | Imbria Pharmaceuticals, Inc. | DOSAGE METHODS FOR TREATMENT OF CARDIOVASCULAR PROBLEMS |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4100285A (en) * | 1976-04-09 | 1978-07-11 | Nippon Shinyaku Co., Ltd. | N-substituted trialkoxybenzyl piperazine derivatives |
| IL283725B2 (en) * | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| EP3866794B1 (en) * | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| US20220168431A1 (en) * | 2019-03-18 | 2022-06-02 | Imbria Pharmaceuticals, Inc. | Methods of treating cancer using trimetazidine-based compounds |
| US20210401833A1 (en) * | 2020-06-30 | 2021-12-30 | Imbria Pharmaceuticals, Inc. | Modified release formulations of modified forms of trimetazidine |
-
2022
- 2022-01-05 US US18/269,820 patent/US20240082242A1/en active Pending
- 2022-01-05 CA CA3206848A patent/CA3206848A1/en active Pending
- 2022-01-05 AU AU2022205937A patent/AU2022205937A1/en active Pending
- 2022-01-05 WO PCT/US2022/011336 patent/WO2022150403A1/en not_active Ceased
- 2022-01-05 JP JP2023540910A patent/JP2024501764A/ja active Pending
- 2022-01-05 IL IL304054A patent/IL304054A/en unknown
- 2022-01-05 KR KR1020237026260A patent/KR20230129250A/ko active Pending
- 2022-01-05 EP EP22737062.4A patent/EP4274436A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501764A5 (https=) | ||
| EP1001801B1 (fr) | Produit comprenant au moins un arn double brin en association avec au moins un interferon pour le traitement de l'hepatite virale | |
| CZ20012947A3 (cs) | Pouľití esenciálních mastných kyselin pro prevenci kardiovaskulárních příhod | |
| JP2003146874A (ja) | 大心血管イベントの一次予防のための多価不飽和脂肪酸の使用 | |
| FR2737121A1 (fr) | Nouvelles formulations galeniques du fenofibrate et leurs applications | |
| JP2011521915A5 (https=) | ||
| AU2004216856A1 (en) | Use of omega-3-fatty acids in the treatment of diabetic patients | |
| FR2543827A1 (fr) | Composition pharmaceutique ayant une activite metabolique et energetique pour utilisation dans la therapeutique cardiaque et vasculaire | |
| JPH0649651B2 (ja) | 心筋虚血治療用医薬組成物 | |
| JP2002534360A (ja) | 疾病治療用製剤及びその使用方法 | |
| JP2009533457A (ja) | Ｃ−ニトロソから誘導されるニトロキシル供与体 | |
| JP2023076632A5 (https=) | ||
| JP2023057082A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| WO2002000258A1 (en) | Medicinal compositions for angiogenic therapy | |
| JP2022031813A (ja) | １５－ｈｅｐｅを含む組成物、およびそれを用いて線維症を処置または防止する方法 | |
| EP1583538A1 (fr) | Utilisation de la 3-methoxy-pregnenolone pour la préparation d'un médicament destiné traiter les maladies neurodegeneratives | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JP7749661B2 (ja) | 心不全の処置のためのクロマノール化合物 | |
| JP2006524190A5 (https=) | ||
| JPH10513186A (ja) | Ｈｉｖプロテアーゼ阻害剤インジナビル及び逆転写酵素阻害剤３ｔｃを必要に応じてａｚｔ、ｄｄｉ、又はｄｄｃと共に用いるｈｉｖ感染の組合せ治療 | |
| FR2651230A1 (fr) | Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et applications comme medicaments. | |
| JP2024540172A5 (https=) | ||
| WO2009092892A2 (fr) | Nouvelle composition pour traiter les effets secondaires des traitements anticancereux | |
| JP2996725B2 (ja) | 動脈硬化の治療のためのラシジピンの使用 | |
| KR20250010046A (ko) | IL-6 및/또는 IL-1β 억제제 |